Labopharm inks $170M distribution deal with Purdue Pharma

Labopharm tapped Purdue Pharma today as US licensee and distributor for the analgesic tramadol. Labopharm expects to submit its new drug application for tramadol to the FDA later this year. The licensing deal nets Labopharm an upfront fee of $20 million plus $40 million on FDA approval; the total cash payments could reach $170 million, plus royalties of 20 percent to 25 percent.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.